Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor

A neurotrophic factor, glial cell technology, applied in nervous system diseases, animal/human proteins, growth factors/inducing factors, etc., can solve the problem of unable to prevent the development of the disease, and achieve the effect of treating Parkinson's syndrome

Inactive Publication Date: 2016-02-10
BEIJING NEWINER BIOTECH CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The clinical manifestations of Parkinson's disease are tremor, rigidity, unstable posture and inability or slow movement. There are about 3 million PD patients in my country. Currently, the treatment of PD is mainly based on drugs, including anticholinergic drugs and amantadine. , levodopa and compound levodopa, these drugs can temporarily improve symptoms, but can not prevent the progression of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor
  • Deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor
  • Deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008] The following examples are only illustrations of the present invention, and do not impose any limitation on the present invention.

[0009] (1) Plasmid construction and engineering bacteria acquisition

[0010] 1. Construction of natural human MANF and dMANF expression plasmids

[0011] According to the amino acid sequences of SeqIDNo1 and SeqIDNo2 respectively, the gene sequences of natural human MANF and deleted MANF were chemically synthesized using the codons favored by Escherichia coli.

[0012] The pGEX-4T-1 vector is used as the expression vector of MANF, which contains the GST chaperone sequence, which can effectively enhance the expression of the target protein and facilitate the downstream purification of the target protein. The pGEX-4T-1 vector was digested with BamHI-SalI, and the large fragment was recovered. After the T4 ligase was used to connect the target gene and the large fragment of the vector, it was transformed into the cloning strain JM109, and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines, particularly a deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease. By carrying out partial delection mutation on an N terminal of the deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor, the obtained deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor has the characteristic of higher activity.

Description

1. Technical field [0001] The invention belongs to the field of genetic engineering drug production. The deletion-type recombinant human midbrain astrocyte-derived neurotrophic factor was obtained by deleting the N-terminal of the human midbrain astrocyte-derived neurotrophic factor. Experiments have shown that the structure has higher specific activity compared with the full-length human midbrain astrocyte-derived neurotrophic factor, and is expected to be developed as a product for the treatment of Parkinson's syndrome. 2. Background technology [0002] Parkinson's disease (Parkinson's disease, PD) is a common neurological disease, and its exact etiological mechanism is still unknown. It is generally believed that it is the result of the joint action of genetic and environmental factors. Among them, oxidative (nitrification) stress, microglial activation and neuroinflammation, mitochondrial dysfunction, protein aggregation and clearance disorders, autophagy stress and oth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/475A61K38/18A61P25/00
Inventor 刘爱华王辉莘旭妮
Owner BEIJING NEWINER BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com